Teclison is a biotechnology company founded in 2014 with a mission to develop groundbreaking therapies for cancer. Specializing in the development of innovative cancer medicines, Teclison's approach focuses on inducing tumor necrosis and enhancing anti-tumor immunity for long-term cancer remission. The company's drug is designed to target any solid tumor with a predilection for liver metastasis, prioritizing hepatocellular carcinoma and metastatic colorectal cancer initially, with plans to expand to other solid tumors with liver metastasis. A first-in-class hypoxia-activating agent forms the basis of Teclison's novel approach, creating high local concentrations within tumors and producing profound hypoxia exclusively within the tumor. The company's latest milestone involves securing a $5.90M venture round investment on 14th February 2022, with participation from Nestor Capital and WTT Investment.
Teclison
Biotechnology company that specializes in the development of innovative cancer medicines
Montclair, United States
9 employees
Venture round
Total: $5.90M
Biotechnology
General Information
Montclair, United States
BounceWatch is an independent company data service, not affiliated with Teclison. To contact Teclison, visit teclison.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Teclison compare?
A PDF of Teclison and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Teclison soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biotechnology
About Teclison
Business keywords: cancer medicines, drug development, tumor necrosis, anti-tumor immunity, liver metastasis, hepatocellular carcinoma, metastatic colorectal cancer, hypoxia-activating agent, cancer cell targeting, cancer stem cells, tumor-promoting macrophages, novel therapies, oncology, pharmaceutical innovation
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | $5.90M | 2 |
|
14 Feb 2022 |
Teclison Alternatives & Competitors
View All Alternatives
We see the future first
Changing the paradigm for cancer treatment through the development of antigen-independent peptide dr...
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of metastatic l...
FAQ About Teclison
Source: BounceWatch company record for Teclison, https://bouncewatch.com/company/teclison, updated 10 October 2024. When citing, please name BounceWatch and link this page.
